Mid-stride at the industrial frontier
The semiconductor lesson nobody learned
Friedman has a way of making geopolitical risk feel concrete. He keeps coming back to semiconductors - not the chips themselves, but the manufacturing base. The U.S. invented the transistor, built the industry, led the world. Then, over several decades, it handed off fabrication to Asia and told itself it was fine because American companies still designed the best chips. Then TSMC became load-bearing infrastructure for global civilization, and the U.S. found itself at the mercy of a supply chain it no longer controlled.
His argument is that biomanufacturing is the same movie, playing out in slow motion, right now. "Someone is going to win this," he has said in multiple forums. "Someone is going to capture the relevant market share, and then it becomes awfully hard to catch up." China is investing billions annually in bioindustrial manufacturing. The EU has been funding the bioeconomy for two decades. The U.S., for all its research excellence and venture capital enthusiasm, has been late to build the industrial layer.
BioMADE exists to interrupt that pattern. It is not a research institute. It is not a VC fund. It is a manufacturing innovation institute — the kind of organization that asks not "can biology make this product?" but "can biology make this product at the scale and cost that wins commercial markets?"
The gap between discovery and factory floor
The problem Friedman is solving has a name in the industry: the valley of death. A research lab can demonstrate that a microbe produces some valuable molecule. A venture-backed startup can get it to a small fermentation tank. But moving from liters to millions of liters — from proof-of-concept to commercial-scale production — requires infrastructure that almost no company can afford to build alone. Pilot plants. Large fermenters. Purification systems. Specialized engineers who have run these processes before.
That infrastructure barely exists in the United States. "We haven't invested enough in large-scale fermentation and purification systems — the backbone of industrial biomanufacturing," Friedman has said. The result: promising U.S. biotech startups license their technology to overseas manufacturers, or relocate operations entirely, because that's where the facilities are.
BioMADE's answer is a network of shared pilot-scale facilities — government-backed, multi-user, accessible to companies that couldn't build their own. The November 2025 groundbreaking at Iowa State University Research Park is the most visible expression of this. A $40 million facility, 15,000 square feet, with food-grade capabilities covering prebiotics, probiotics, sweeteners, and flavors. Funded jointly by BioMADE ($20M), the Iowa Economic Development Authority ($10M), and Iowa State University ($10M). Expected to open in 2027.
No premium for green
One of Friedman's most bracing public positions is his bluntness about sustainability economics. In an industry that often leans on environmental virtue as a selling point, he is direct: "There's no premium for green. Customers won't pay extra for sustainability." Bio-based products have to compete on price and performance — not on moral appeal — or they don't scale.
This isn't cynicism. It's engineering pragmatism applied to market dynamics. If a bio-based plastic or lubricant or surfactant costs more than the petroleum-derived alternative and performs no better, it won't achieve the market penetration needed to matter environmentally. Friedman's argument is that the only way biology actually displaces fossil-based materials is if biomanufacturing becomes genuinely cost-competitive — which requires exactly the kind of infrastructure investment he's building.
Two institutions, one arc
Before BioMADE, Friedman built EBRC — the Engineering Biology Research Consortium — from the ground up starting in 2016. He was its founding Executive Director and President, a role he held until 2021. EBRC is a nonprofit membership organization focused on advancing precompetitive technologies in synthetic biology and engineering biology, with an emphasis on safe, secure, sustainable, and ethical practice.
The move from EBRC to BioMADE tracks a career-long logic: start with the science, understand the policy, then build the institutions that translate one into the other. At the National Academies of Sciences, Engineering, and Medicine, where Friedman served as a study director on the Board on Chemical Sciences and Technology, he learned how to take complex scientific topics and make them legible to policymakers — a skill that runs through everything he's done since.
A stint as a Special Government Employee at the White House Office of Science & Technology Policy gave him direct exposure to how federal priorities get set around biomanufacturing. That experience informed the structure of BioMADE itself — a Manufacturing Innovation Institute model that brings together government funding, academic partnerships, and industry membership to solve problems no single actor could tackle alone.
The feedstock advantage
One of Friedman's recurring arguments is that the United States has an underappreciated structural advantage in the coming bioindustrial competition: agricultural feedstocks. Biomanufacturing runs on sugars, starches, plant-based inputs — the raw material that microbes ferment into products. And no country in the world grows corn at the scale and efficiency that the American Midwest does.
"There's no place better in the world at growing corn than the United States," he has said. "We have a global feedstock advantage, and if we build the right manufacturing infrastructure, we can dominate this industry." The Iowa facility, with its focus on food-grade fermentation ingredients, is one expression of that thesis — situating biomanufacturing capacity in the agricultural heartland that will supply it.
His time horizon on all of this is deliberately long. "Developing a manufacturing sector takes time and long-term dedication to winning," he has said. "This isn't a one-year or one-quarter thing. It's a 50-to-100-year effort." For a sector accustomed to thinking in startup cycles, that's a provocative frame. It's also, arguably, the only frame that makes sense for what he's trying to build.